Post-Switch Market Exclusivity Benefits Everyone, Insists Global Switch Expert
Executive Summary
Three- to five-year market exclusivity periods for switched products would not only incentivize consumer healthcare firms but also enable pre- and post-switch data to be generated more easily, thus improving the quality of switch applications, explains global switch expert Dr Natalie Gauld in the final part of our exclusive interview.
You may also be interested in...
Are Rx-To-OTC Switches Worth The Trouble? Yes They Are, IQVIA Data Shows
The holy grail of consumer health innovation, Rx-to-OTC switches, are costly and hard to pull off. So, are they worth the effort? An analysis by IQVIA of desloratadine, which was switched in Germany 2020 by Novartis subsidiary, Hexal, shows that they are, with sales of OTC desloratadine products growing 112% between 2019 and 2020.
Norway Model Offers Key To Unlock More Complex Switches
Norway's move to encourage more innovative Rx-to-OTC switches has begun to bear fruit with the recent reclassification of Pfizer's Viagra. The country's decision to introduce a new non-prescription drug category to promote switching can be used as a model for securing a new wave of more complex switches elsewhere around the world.
Global Industry Welcomes World Health Organization’s Call For Widespread Oral Contraceptive Rx-To-OTC Switch
The Global Self-Care Industry Federation (previously the WSMI) welcomes a call from the World Health Organization to make oral contraceptive pills available OTC.